

### **REMARKS / ARGUMENTS**

Claims 1-11, 14, 16-19 and 23-33 are currently pending. Claims 12-13, 15 and 20-22 have been canceled. Claims 1, 11, 14, 16, 23, 28 and 33 have been amended for the purposes of expediting prosecution. In view of the following amendments, a withdrawal of all rejections and a Notice of Allowability are respectfully solicited. Applicants submit that no new issues are raised by virtue of this amendment and that the claims are in condition for immediate allowance.

Claims 1-8, 10-12, 14 and 16-33 are rejected under 35 U.S.C. § 112, first paragraph, for lack of enablement. In one aspect, the Office maintains its rejection of claims that recite "solvates thereof". Applicants have amended the above-mentioned claims to address this issue. This enablement rejection is now believed to be moot. Applicants submit that such an amendment does not constitute acquiescing to this rejection.

Claims 12, 14 and 20-22, directed to methods of use, are rejected for not being enabled. Applicants have canceled Claims 12 and 20-22; Claim 14 is maintained since it is directed to a pharmaceutical formulation and not a method of use. Applicants submit that such a claim cancellation does not constitute acquiescing to this rejection.

Claims 1-8, 10-12, 14 and 16-33 have been rejected under 35 U.S.C. § 112, second paragraph, for indefiniteness. The Office objects to the proviso language referring to the variable R1 being H. Applicants have amended the claim to address this issue.

In view of the above, a withdrawal of all outstanding rejections is respectfully solicited, along with a Notice of Allowability.

Respectfully submitted,

Dated: September 21, 2007

/Robert J. Smith/  
Robert J. Smith  
Attorney for Applicant  
Reg. No. 40,820  
Tel. (919) 483-9616  
Fax. (919) 483-7988